Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke

Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-generation treatment for acute ischemic stroke.